Bioequvalence studies for levothyroxine

AAPS Journal

Volumn 7, Issue 1, 2005, Pages

  Bolton, Sanford ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; LEVOTHYROXINE; THYROTROPIN; BIOLOGICAL MARKER; THYROXINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HUMAN; PRACTICE GUIDELINE; PUBLIC HEALTH; ALGORITHM; BIOAVAILABILITY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; EPIDEMIOLOGY; HYPOTHYROIDISM; METHODOLOGY; PHARMACEUTICS; PHARMACOKINETICS; REVIEW; SECRETION; STANDARD; THYROID GLAND; UNITED STATES;

ALGORITHMS; AREA UNDER CURVE; BIAS (EPIDEMIOLOGY); BIOLOGICAL AVAILABILITY; BIOLOGICAL MARKERS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, GENERIC; GUIDELINES; HUMANS; HYPOTHYROIDISM; REFERENCE STANDARDS; THERAPEUTIC EQUIVALENCY; THYROID GLAND; THYROTROPIN; THYROXINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 27644545773     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070106     Document Type: Article

References (13)

1. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing. Rockville, MD: February 2001.
2. Citizen's Petition. Jones Pharma, Inc. March 28, 2003.
3. Citizen's Petition. Abbott Laboratories. August 25, 2003.
4. Blakesley V, Awni NV, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 2004;14:191-200.
5. Food and Drug Administration. FDA Advisory Committee for Pharmaceutical Science. Briefing Document From Abbott Laboratories. Rockville, MD; May 12-13, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3926B1_02_A-Abbot%20.htm. Accessed March 23, 2005.
6. Mylan Laboratories, Inc. Levothyroxine Sodium Tablets. Canonsburg, PA: Mylan Laboratories, Inc; 2000:76-187.
7. Food and Drug Administration. FDA Advisory Committee for Pharmaceutical Science. Record of Proceedings. March 13, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/cder03.html# PharmaceuticalScience. Accessed March 23, 2005.
8. Citizen's Petition. Abbott Laboratories. August 25, 2003.
9. Food and Drug Administration. FDA Response to Abbott Petition, Citizen's Petition #2003P-0126/CP1, Document PDN 1. June 29, 2004.
10. Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. J Clin Endocrinol. 1988;28:325-333.
11. Food and Drug Administration. Code of Federal Regulations. Title 21, Volume 5: CFR 320.33. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=320.24. Accessed: March 23, 2005.
12. Bolton S, Bon C. Pharmaceutical Statistics, Practical and Clinical Applications. 4th ed. New York, NY: Marcel Dekker; 2003.
13. Health Canada. Expert Advisory Committee on Bioavailability. Record of Proceedings. April 16, 2003. Available at http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/2003-04-16_e.html. Accessed March 23, 2005.